Saint Therapeutics

Saint Therapeutics is a clinical-stage biotechnology company dedicated to revolutionizing tissue repair and metabolic health. The company's core technology is based on over 20 years of research into the scarless healing properties of fetal skin, specifically the role of the protein fibromodulin (FMOD). Its lead candidate, SLI-F06, is a first-in-class peptide drug designed to activate fibroblasts to promote rapid, high-quality wound healing while significantly reducing scar formation. Beyond dermatology, Saint Therapeutics is developing a diverse pipeline targeting metabolic-associated steatohepatitis (MASH) and liver toxicity, including an antidote for acetaminophen overdose. The company has successfully completed Phase 1 and Phase 2a clinical trials for its lead scar reduction program and continues to expand its platform into internal fibrotic and regenerative applications.